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Abstract
Background: MircoRNAs(miRNAs) are short, endogenously non-coding RNAs. The abnormal
expression of miRNAs may be valuable for the diagnosis and treatment of tumors.
Methods: To screening the special miRNAs in gastric carcinoma, expression level of miRNAs in
gastric carcinoma and normal gaster samples were detected by miRNA gene chip. Then, the
expressions of miR-9 and miR-433 in gastric carcinoma tissue and SGC7901 cell line were validated
by qRT-PCR. GRB2 and RAB34, targets of miR-433 and miR-9 respectively, were detected by
Western blot.
Results:  We found 19 miRNAs and 7 miRNAs were down-regulated and up-regulated
respectively. Compared with normal gaster samples, our data showed that miR-9 and miR-433
were down-regulated in gastric carcinoma. Meanwhile, we also found that miR-433 and miR-9
regulated the expression levels of GRB2 and RAB34 respectively.
Conclusion: Our data show miR-9 and miR-433 was down-regulated in gastric carcinoma. The
targets of miR-433 and miR-9 were tumor-associated proteins GRB2 and RAB34 respectively. This
result provided the related information of miRNAs in gastric carcinoma.
Background
Gastric cancer is the fourth most common malignancy
and the second cause of death [1]. Many studies indicated
that gastric carcinoma is a polygenic disease with multi-
step processes for the abnormal development of many
related genes [2]. However, the regulatory mechanism
involved in the development of canceration is still not
well understood.
Recently, researchers have found a new class of short,
endogenously non-coding RNAs called microRNAs(miR-
NAs) in animals and plants [3-5]. They regulate the
expression of protein-coding genes via degrading or
inhibiting the translation of the targeted mRNAs[6]. Accu-
mulated evidences demonstrated miRNAs play important
role in carcinogenesis. Xiao indicated miRNA-106a (miR-
106a) had oncogenic activity in humans. The level of miR-
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106a in cancer tissues was significantly higher than that in
non-tumor tissues expression [7]. Another paper showed
that restoration of tumor suppressor miR-34 inhibits
human p53-mutant gastric cancer tumorspheres [8].
Together, these observations suggest the possible exist-
ence of cancer-specific miRNAs. For this reason, miRNAs
expression profiling has been investigated in different
kinds of cancer to identify cancer-specific miRNAs [9-13].
In the present study, we detected the expression profiling
of 328 miRNAs in 2 cell lines, 24 gastric cancer samples
and 3 normal gastric tissue samples, revealing the miRNA
characteristics of gastric cancer. Furthermore, our data
suggested significantly down-regulated miR-433 and miR-
9, which were considered as the modulator of GRB2 and
RAB34 respectively. GRB2 and RAB34 were involved in
the molecular pathogenesis of gastric cancer.
Methods
Gastric tissues and cell lines culture
All human gastric tissue samples including 3 normal gas-
tric tissues and 24 malignant tissues (2 in early phase and
22 in late phase of gastric cancer) were obtained from
General surgery dept. of the First and Second Affiliated
Hospital of Chongqing Medical University (Chongqing,
China). All the patients signed the informed consent. The
tissues were stored in liquid nitrogen after removing from
patients. Gastric cancer cell SGC7901 was donated by
Viral Hepatitis Research Institute of Chongqing Medical
University (Chongqing, China). Gastric cell line GES-1
was purchased from Cancer Institute and Hospital of Chi-
nese Academy of Medical Sciences (Beijing, China). Both
cell lines were cultured in serum-free Roswell Park Memo-
rial Institute (RPMI) 1640 medium supplemented with
10% low-endotoxin FCS.
Total RNA preparation
Total RNAs were extracted from malignant tissues, normal
gastric tissues, SGC7901 and GES-1 respectively by using
Trizol in accordance with the manufacturer's instructions.
The total RNAs were quantified by ultraviolet spectropho-
tometer at 260 nm.
miRNA microarray hybridization
Total 33 miRNA microarrays were used to examine
miRNA expression profiling. 3 miRNA microarrays were
used for 3 normal gastric tissues, 24 miRNA microarrays
were used for 24 malignant tissues, and 6 for SGC7901
and GES-1 cell lines. 5 μg total RNAs from each sample
were used for miRNA labeling. Then, miRNA array hybrid-
izations were performed on miRNA microarray. A Gene-
Pix 4000B scanner (Axon Instruments) was employed to
detect hybridization signals via streptavidin-Alexa Fluor
647 conjugation. Images were quantified by the GenePix
Pro 6.0(Axon Instruments).
Reverse transcription
The total RNAs were reverse transcribed to synthesize
cDNA. The RT Primers were designed by Primer 5.0 soft-
ware and shown in Table 1. The 20 μl reaction system
included 2 μl dNTPs (HyTest Ltd), 2 μl 10× RT Buffer (Epi-
centre), 1 μl RTspecific primer, 1 μg Total RNA, 2 μl M-
MLV reverse transcriptase (Epicentre), 0.3 μl RNase inhib-
itor (Epicentre) and nucleas-free ddH2O. The reaction was
performed at 16°C for 30 min, 42°C for 42 min followed
by 85°C for 5 min. The process was performed in Gene
Amp PCR System 9700 (Applied Biosystems). The reverse
transcription products were stored at -20°C for use.
Quantitative Real-time PCR
The expressions of miR-9 and miR-433 in 29 samples
were identified by qRT-PCR. The interested miRNAs and
an interior reference U6  were run in Rotor-Gene 3000
Real-time PCR (Corbett Research). Real-time PCR primers
were shown in Table 2. 25 μl PCR mixture included 2.5 μl
dNTPs (HyTest Ltd), 2.5 μl 10 × PCR Buffer (Promega),
1.5 μl MgCl2 liquor (Promega), 1 unit Taq polymerase
(Promega), SybergreenI (Invitrogen) final concentration
0.25×, 1 μl PCR specific primer forward and reverse, 1 μl
reverse transcription product and nucleas-free water. The
reactions were performed at 95°C for 5 min, then fol-
lowed by 40 cycles of 95°C for 10 s and 60°C for 1 min.
The expression of miRNA was measured by Ct(threshold
cycle). The Ct represented the fractional cycle number
when the fluorescence of each sample passed the fixed
threshold. The ΔΔCt method determined miRNA expres-
sion level. The change was generated using the equation:
2 -ΔΔCT.
Prediction and clone of miRNA target
Predicted targets of miRNA were determined by the algo-
rithms: TargetScan, PicTar, and miRanda. In this way, we
found that RAB34 and GRB2 were the predicted targets of
miR-9 and miR-433 respectively. The 3'-UTR target sites of
the human RAB34 and GRB2 were synthesized and
Table 1: Reverse transcription primers
Gene name RT primer
U6 5'CGTTCACGAATTTGCGTGTCAT3'
hsa-miR-9 5'GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACTCATACAG3'
hsa-miR-433 5'GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACTCACACCG3'Journal of Experimental & Clinical Cancer Research 2009, 28:82 http://www.jeccr.com/content/28/1/82
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cloned in the downstream of the luciferase gene of pGL3-
control. The plasmids including junction fragments of
norientation were screened by PCR. Amplification prim-
ers of Plasmid containing miR-9 target (about 430 bp
products): forward (5'-TGGACGAAGTACCGAAAGGT-3')
and reverse (5'-GGCACAGTGAGAGGCTGGAATCAT-
TAAGCATCCTCAAAC); The Amplification primers of
Plasmid containing miR-433 target (about 580 bp prod-
ucts): forward (5'-TGGGAGTCTCCCTCCGACTCCAGA-
TATGAA-3') and reverse (5'-
CACTGCATTCTAGTTGTGGT-3'). Both plasmids were
identified by XbaI  digestion and electrophoresis. The
sequenced plasmids were named pGL3-miR-9 and pGL3-
miR-433 and used for SGC7901 cell transfection.
Transfection and assay of luciferase activity
To examine the luciferase activity, 4 groups were set up for
miR-9 and miR433. Respectively, ①SGC7901 (blank con-
trol),  ✍pGL3,  ③pGL3-miR-9,  ④hsa-miR-9 (Takara Co.,
Ltd. Danian, China)+ pGL3-miR-9 for miR-9 and
①SGC7901 (blank control), ✍pGL3,  ③pGL3-miR-433,
④hsa-miR-433 (Takara Co., Ltd. Danian, China) + pGL3-
miR-433 for miR-433. SGC7901 cells were seeded in 6-
well plates for 24 h before the transfection. When the cell
were 50%~60% confluence, 2 μg of plasmids were trans-
fect in each group. Transfection was performed using
Lipofectamine 2000 (Invitrogen)according to the manu-
facturer's procedure. After the 48 h transfection, luciferase
activity was assayed and analyzed by relative light unit
(RLU).
Western blot analysis
To evaluate regulation of RAB34 and GRB2 by miR-9 and
miR-433, SGC7901 was transfected with miR-9 and miR-
433 in a 6-well plate according to manufacturer's proce-
dure. For both miR-9 and miR-433, there were three
groups including ①control group; ✍group 1: 50 pmol of
miR-9 or miR-433 was transfected; ③group 2: 100 pmol of
miR-9 or miR-433 was transfected. After 48 h transfection,
the cells were harvested and total protein and total RNA
were extracted. RAB34 and GRB2 expression levels were
detected by Western blot. MiR-9 and miR-433 level were
mesured by qRT-PCR respectively.
Statistics and presentation of data
All data are expressed as means ± standard deviation. Each
experiment was repeated at least 6 times. The t test was
used to examine the differences between groups. A p value
of less than 0.05 was considered as significance.
Results
Expressive characteristics of miRNA in gastric cancer 
tissues and cell lines
A conventional microarray platform was used to evaluate
miRNA expression profiling in 3 normal gastric tissues, 24
malignant tissues, SGC7901 and GES-1 cell lines. Com-
pared with that in the normal gastric samples, 26 miRNAs
expressed abnormally in gastric carcinoma samples. 19
miRNAs of these were down-regulated (the expression in
the normal group was more than twice as high as in the
carcinoma group). 7 miRNAs were up-regulated (the
expression in the carcinoma group was more than twice as
high as in the normal group). The differentially expressive
miRNAs were listed in Table 3.
Table 2: Quantitative Real-time PCR primers
Gene name Primer sequence Anneal temperature(°C) Product length (bp)
U6 F:5'GCTTCGGCAGCACATATACTAAAAT3' 60 89
R:5'CGCTTCACGAATTTGCGTGTCAT3'
hsa-miR-9 F:5'GGGTCTTTGGTTATCTAGC3' 60 64
R:5'TGCGTGTCGTGGAGTC3'
hsa-miR-433 F:5'GGATCATGATGGGCTCCT3' 60 63
R:5'CAGTGCGTGTCGTGGAGT3'
Table 3: miRNAs differential expression in gastric cancer 
samples compared with the normal samples
Down-regulation (19) P Value Up-regulation (7) P Value
miR-9 0.0073 miR-518b 0.009
miR-433 0.0041 miR-26b 0.0147
miR-490 0.0142 miR-212 0.0329
miR-155 0.021 miR-320 0.0179
miR-188 0.019 miR-409-3b 0.0352
miR-630 0.024 miR-30a-5b 0.0164
miR-503 0.0102 miR-379 0.0158
miR-611 0.0151
miR-545 0.0241
miR-567 0.0173
miR-575 0.0109
miR-197 0.024
miR-649 0.0157
miR-19b 0.017
miR-338 0.0184
miR-383 0.0267
miR-652 0.0183
miR-551a 0.0166
miR-370 0.0112Journal of Experimental & Clinical Cancer Research 2009, 28:82 http://www.jeccr.com/content/28/1/82
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Detection of miR-433 and miR-9 expression by 
Quantitative Real-time PCR
MiR-433 and miR-9 were remarkably down-regulated by
microarray analysis in the carcinoma samples. qRT-PCR
was used to detect the expressive level of miR-433 and
miR-9 in 3 normal gastric tissues, 24 malignant tissues,
SGC7901 and GES-1 cell lines. We found that miR-433
was down-regulated 83% in the carcinoma tissues com-
pared with normal gastric tissues. MiR-433 was down-reg-
ulated 77.3% (P < 0.05) in SGC7901 compared with GES-
1 cell lines (Figure 1A). MiR-9 was down-regulated 75% in
carcinoma tissues compared with normal gastric tissues.
MiR-9 was down-regulated 76.2% (P < 0.05) in SGC7901
compared with GES-1 cell lines (Figure 1B). The results
were consistent to the microarray analysis.
Identification of miR-9 and miR-433 targets
We were further interested in miRNA-regulated gene tar-
gets, which enabled us to understand miRNA functions.
To explain the potential roles of miR-9 and miR-433 in
carcinogenesis, we predicted the targets of miR-9 and
miR-433 via the algorithms: TargetScan, PicTar, and
miRanda. To confirm whether the predicted targets of
miR-9 and miR-433 were responsible for their regulation,
the presumed target sites were cloned and inserted at the
downstream of the luciferase gene of pGL3. Direction of
junction fragments was identified and plasmids including
junction fragments of norientation were chose. In Figure
(2A), we found a 430 bp fragment, and in Figure (3A), we
found a 580 bp fragment. The results were consistent to
the amplification of pGL3-control and junction fragments
sequences, which demonstrated that the fragments were
norientation. XbaI was used to digest the junction frag-
ments, then, we did electrophoresis. In Figure (2B) and
Figure (3B), 360 bp fragments were objective fragments.
The fragment was sequenced and inserted into plasmids.
We measured luciferase activity and the relative light unit
(RLU) at 48 h after the transfection. Luciferase activity of
cells cotransfected pGL3-miR-9 and hsa-miR-9 decreased
50% compared with pGL3-miR-9 (P < 0.05) (Figure 4A).
Luciferase activity of cells cotransfected pGL3-miR-433
and hsa-miR-433 decreased by 54% compared with
pGL3-miR-433 (P < 0.05) (Figure 4B).
The expression level of RAB34 and GRB2 were measured
after miR-9 or miR-433 were transfected into SGC7901.
The expression of RAB34 decreased 45% in group 1 and
72% in group 2 compared with control group (P < 0.05)
(Figure 5A). The expression of GRB2 decreased 53% in
group 1 and 89% in group 2 compared with control group
(P < 0.05) (Figure 5B). Meanwhile, we measured the level
MiR-433 and miR-9 expression in normal gastric tissues, 24 malignant tissues, SGC7901 and GES-1 cell lines Figure 1
MiR-433 and miR-9 expression in normal gastric tissues, 24 malignant tissues, SGC7901 and GES-1 cell lines. A, 
miR-433 was down-regulated 83% in the carcinoma tissues compared with normal gastric tissues and down-regulated 77.3% (P 
< 0.05) in SGC7901 compared with GES-1 cell lines. B, miR-9 was down-regulated 75% in carcinoma tissues compared with 
normal gastric tissues and down-regulated 76.2% (P < 0.05) in SGC7901 compared with GES-1 cell lines.Journal of Experimental & Clinical Cancer Research 2009, 28:82 http://www.jeccr.com/content/28/1/82
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of miR-9 and miR-433 by qRT-PCR. MiR-9 level increased
1.3-fold and 2.8-fold respectively in group 1 and 2 com-
pared with control group (P < 0.05) (Figure 6A). MiR-433
level increased1.6-fold and 3.0-fold in group 1 and 2 com-
pared with control group (P < 0.05) (Figure 6B).
Discussion
Recent researches indicated some miRNAs were down-
regulated in human malignancies. Meanwhile, these miR-
NAs could be used to classify histotypes of tumors, distin-
guish cancer tissue from normal tissue [14-17]. In present
study, the expression of 328 miRNAs in 3 normal gastric
tissues, 24 malignant tissues, SGC7901 and GES-1 were
detected to screen specific miRNAs markers for gastric car-
cinoma. 26 miRNAs were found expression abnormally in
gastric carcinoma samples. 19 miRNAs was down-regu-
lated and 7 miRNAs were up-regulated. The number of the
down-regulated miRNAs in carcinoma samples was more
than that of the up-regulated ones in the past studies on
tumor related miRNAs [9,14], which was consistent to our
former results. The absence of mechanism of miRNAs
maturation might explain the general down-regulation of
miRNAs in tumors [18]. However, miRNAs maturation
was activated in some studies [19], which was the reason
for the unclear role of miRNAs maturation procession in
tumorigeness.
Cloning of miR-9 target gene Figure 2
Cloning of miR-9 target gene. A, identification of junction fragment of norientation. There was a 430 bp fragment, which 
demonstrated that the fragment was norientation. B, junction fragment digested by XbaI. The 360 bp fragment was destination 
fragment.
Cloning of miR-433 target gene Figure 3
Cloning of miR-433 target gene. A, identification of junction fragment of norientation. There was a 580 bp fragment, which 
demonstrated that the fragment was norientation. B, junction fragment digested by XbaI. The 360 bp fragment was destination 
fragment.Journal of Experimental & Clinical Cancer Research 2009, 28:82 http://www.jeccr.com/content/28/1/82
Page 6 of 9
(page number not for citation purposes)
Although different types of tumors may have the same
miRNAs markers, there are specific miRNAs in tumors
from different cellular origins [20]. In this study, majority
of the differentially expressive miRNAs have not been
reported in other tumors, especially miR-433 and miR-9.
Both of them were down-regulated significantly in gastric
carcinoma tissue and SGC7901 cell line, suggesting they
might be the special markers for gastric carcinoma.
The differential expressions of miRNAs suggest miRNAs
may be involved in the genesis and development of
tumor. Up to now, the relation between down-regulated
miRNAs and tumorigenesis was not well understood.
Although bioinformatics could be used to predict the tar-
gets of miRNAs, these targets still need to be confirmed by
experiment. Studies have confirmed that miRNAs could
regulate the expressions of oncogenes. For example, miR-
NAs of let-7 family could regulate 3 members of RAS
oncogene family [21] and miR-15a/miR-16-1 could regu-
late BCL2 [22], which supported the down-regulated miR-
NAs were involved in tumors nosogenesis. MiR-9 and
miR-433 were found down-regulated significantly in gas-
tric carcinoma samples, suggesting they might play impor-
tant roles in the cancerigenic process. Meanwhile, we
confirmed that RAB34, GRB2 were down regulated by
miR-9 and miR-433 respectively, which revealed the
potential mechanism for gastric carcinoma genesis.
RAB34 is a member of RAS oncogene family. It is a guano-
sine triphosphatase (GTPases) which can regulate bud-
ding, junction and fusion of vesicle in exocytosis and
endocytosis pathway [23]. GRB2, an adaptor protein, is a
growth factor binding protein. GRB2 binds to the phos-
phorated tyrosine residue of the receptor via SH2 domain
after receptor tyrosine kinase (RTK) is activated. Mean-
while, GRB2 binds to proline enrichment region of Sos
protein via its SH3 domain and formed receptor-GRB2-
Sos signal transduction complex. Sos stimulates proximal
Ras to release GDP and bind to GTP, which leads to the
miR-9 and miR-433 down regulated luciferase activity of RAB34 and GRB2 Figure 4
miR-9 and miR-433 down regulated luciferase activity of RAB34 and GRB2. A, miR-9 regulated luciferase activity by 
integrating the binding site in the 3'-UTR of RAB34. Luciferase activity of SGC7901 cotransfected pGL3-miR-9 and hsa-miR-9 
decreased 50% compared with pGL3-miR-9 (P < 0.05). B, miR-433 regulated luciferase activity by integrating the binding site in 
the 3'-UTR of GRB2. Luciferase activity of SGC7901 cotransfected pGL3-miR-433 and hsa-miR-433 decreased 54% compared 
with pGL3-miR-433 (P < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:82 http://www.jeccr.com/content/28/1/82
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miR-9 and miR-433 down regulated RAB34 and GRB2 expression in SGC7901 cell line Figure 5
miR-9 and miR-433 down regulated RAB34 and GRB2 expression in SGC7901 cell line. A, RAB34 decreased 45% 
and 72% compared with control group after 50 pmol (group 1) and 100 pmol (group 2) hsa-miR-9 transfection. Relative gray 
scale value was compared with β-actin. B, GRB2 decreased 53% and 89% compared with control group after 50 pmol (group 1) 
and 100 pmo l (group 2) hsa-miR-433 transfection. Relative gray scale value was compared with β-actin.
MiR-9 and miR-433 increased after hsa-miR-9 and hsa-miR-433 transfection Figure 6
MiR-9 and miR-433 increased after hsa-miR-9 and hsa-miR-433 transfection. A, miR-9 level increased 1.3-fold and 
2.8-fold respectively after 50 pmol (group 1) and 100 pmol (group 2) hsa-miR-9 transfection. B, miR-433 level increased 1.6-
fold and 3.0-fold respectively after 50 pmol (group1) and 100 pmol (group 2) hsa-miR-433 transfection. (P < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:82 http://www.jeccr.com/content/28/1/82
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activation. Once activated, Ras activates various signal
transduction proteins in different signal pathways of the
downstream. Mitogen-activate-protein kinases (MAPKs)
system is an important pathway among them. MAPK
plays an important role in cell growth, proliferation, dif-
ferentiation. Meanwhile, it is involved in cellular stress
reaction. In this study, we found the expressive levels of
miR-433 and miR-9 was significantly down-regulated in
gastric cancer tissues and SGC7901. MiRNAs also can
silence gene. The down-regulation of miR-433 and miR-9
attenuated the gene silencing, which activated GRB2 and
RAB34.
In summary, we found miRNAs expressions profiling in
human gastric carcinoma, and focused on the screen and
identification of targets of the abnormally expressive miR-
NAs. Our results showed miR-433 and miR-9 was signifi-
cantly down-regulated and might be used as a marker for
the advanced gastric carcinoma. In addition, we also
found miR-433 and miR-9 targeted GRB2 and RAB34,
which was favorable for explaining carcinogenesis path-
way mediated by miRNAs and screening the therapeutic
targets. Some researchers have found that successive short
RNAs injection could affect liver effectively in vivo
[24,25], which established a good model for the develop-
ment of miRNA-based approach of gene therapy. Our
results show the differentially expressive miRNAs in gas-
tric carcinoma, which will provide related data for molec-
ular targeted therapy based on miRNAs.
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